PRESS RELEASE
May 31, 2016
Saniona, a leading biotech company in the field of ion channels, today announces that it has acquired all rights including patents and data to NeuroSearch A/S's remaining product portfolio comprising two compounds, ACR325 and ACR343. The agreement does not trigger any up-front payment. As full consideration for the asset transfer, NeuroSearch will receive up to 20 percent of any future payments to Saniona in relation to the potential out-licensing of the two compounds.
"The acquisition will have no or marginal effect on Saniona's financial position in 2016. The two compounds will not be actively developed by Saniona but are made available for partners. ACR325 and ACR343 will not be part of our current active pipeline," says Jørgen Drejer, CEO of Saniona.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com
About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 4,400 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com.
HUG#2016750
Attachments:http://www.globenewswire.com/NewsRoom/AttachmentNg/47ded49d-edd2-4efd-8d71-0555934eac75
